New study compares odevixibat to natural course of rare liver disease
NCT ID NCT07497724
First seen Apr 08, 2026 · Last updated May 22, 2026 · Updated 6 times
Summary
This study looks at how the drug odevixibat affects long-term health in people with a rare liver disease called PFIC. Researchers compared patients who took odevixibat in earlier trials to similar patients who did not receive the drug. The goal is to see if odevixibat helps avoid liver transplants, surgery, or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PFIC - PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Not applicable - retrospective secondary use of data
Paris, France
Conditions
Explore the condition pages connected to this study.